| Combination of | |
|---|---|
| Budesonide | Inhaled corticosteroid |
| Glycopyrronium bromide | Anticholinergic muscarinic antagonist |
| Formoterol | Long-acting β2 agonist |
| Clinical data | |
| Trade names | Breztri Aerosphere, Trixeo Aerosphere, Riltrava Aerosphere |
| Other names | Budesonide/glycopyrrolate/formoterol fumarate |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration |
By mouth (inhalation) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Budesonide/glycopyrronium bromide/formoterol, sold under the brand name Breztri Aerosphere among others, is an inhalable fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). It contains budesonide, glycopyrronium bromide, and formoterol fumarate dihydrate. It is inhaled.
The most common side effects include oral candidiasis (a fungal infection of the mouth), upper respiratory tract infection, pneumonia, back pain, muscle spasms, influenza, urinary tract infection, cough, sinusitis, and diarrhea. Headache is also a common side effect.
The combination was approved for medical use in the United States in July 2020, and in the European Union in December 2020.
Medical uses
Budesonide/glycopyrronium bromide/formoterol is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
Society and culture
Legal status
Trixeo Aerosphere was approved for medical use in the European Union in December 2020. Riltrava Aerosphere was approved for medical use in the European Union in January 2022.
See also
External links
- "Budesonide". Drug Information Portal. U.S. National Library of Medicine.
- "Glycopyrronium bromide". Drug Information Portal. U.S. National Library of Medicine.
- "Formoterol fumarate". Drug Information Portal. U.S. National Library of Medicine.
